Condition: Extensive-stage Small-cell Lung Cancer · Sponsor: Universität des Saarlandes
Open-label, single-arm, prospective multicenter phase II clinical trial to determine the efficacy of immunotherapy with durvalumab concomitant with radiochemotherapy, followed by durvalumab maintenance therapy in combination with stereotactic radiotherapy in extensive stage SCLC
This description comes directly from the study's public registry record.
Wiebke Pirschel, M.Sc. · +49684116 · wiebke.pirschel@uks.eu
Markus Hecht, Prof. · +49684116 · markus.hecht.clinicaltrials@uks.eu
Always discuss trial participation with your own doctor first.
| University Hospital Augsburg, Radiation Oncology | Augsburg, Bavaria, Germany | Recruiting |
| University Hospital Erlangen, Radiation Oncology | Erlangen, Bavaria, Germany | Recruiting |
| University Hospital Regensburg, Clinic and Polyclinic for Radiotherapy | Regensburg, Bavaria, Germany | Recruiting |
| Kliniken Maria Hilf | Mönchengladbach, North Rhine-Westphalia, Germany | Recruiting |
| Saarland University Medical Center and Saarland University Faculty of Medicine, Clinic for Radiotherapy and Radiooncology | Homburg, Saarland, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06223711